Autres langues CStone Pharmaceuticals OTC Markets

Actions

CSPHF

KYG2588M1006

Produits pharmaceutiques

Marché Fermé - OTC Markets Autres places de cotation 21:21:14 10/07/2026			Varia. 5j.	Varia. 1 janv.
0,7100 ^USD	+19,43%		-.--%	-20,49%

20/07	CStone Pharmaceuticals annonce la mise à jour de ses données cliniques et deux présentations à l'ESMO 2026 pour l'anticorps trispécifique CS2009	CI
26/06	CStone Pharma confie la commercialisation du sugemalimab à Arrotex en Australie et en Nouvelle-Zélande	MT

Autres langues

20/07	Cstone Pharmaceuticals Announces Updated Clinical Data and Esmo 2026 Presentations for Cs2009 Trispecific Antibody
29/06	MÄRKTE ASIEN/Positive Vorzeichen überwiegen - Anleger setzen auf Ende des Iran-Kriegs
29/06	MÄRKTE ASIEN/Uneinheitlich - Pharmawerte in China haussieren
26/06	CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
26/06	CStone Pharma Taps Arrotex to Commercialize Sugemalimab in Australia, New Zealand
25/06	CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex Pharmaceuticals for Sugemalimab Across Australia and New Zealand
12/06	CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
12/06	CStone Pharmaceuticals Drug Receives Ethics Approval in Australia
12/06	CStone Announces Global Multicenter Phase I Clinical Trial of Its Pipeline 2.0 Core Candidate CS5007 Receives Ethics Approval from the Australian Human Research Ethics Committee
11/06	CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
11/06	Cstone Presents Clinical Data for Cs2009 Trispecific Antibody At Asco 2026
01/06	Cstone Pharmaceuticals Presents Updated Clinical Data for Cs2009 Trispecific Antibody At Asco 2026
01/06	ASCO 2026 \| CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
13/05	CStone Pharmaceuticals Plans Share Buyback
11/05	CStone Pharmaceuticals Initiates Nationwide Commercial Supply Of Locally Manufactured Pralsetinib Capsules
11/05	CStone Pharmaceuticals begins nationwide commercial supply of locally manufactured pralsetinib capsules
11/05	CStone Pharmaceuticals Begins Commercial Distribution of Locally Manufactured Pralsetinib
23/04	CStone Pharmaceuticals Completes HK$1.05 Billion Share Offering
22/04	CStone Pharmaceuticals Announces Updated Clinical Data for CS2009 Trispecific Antibody
20/04	Cstone Pharmaceuticals Presents Preclinical Data for Three Novel or Differentiated Adcs At Aacr 2026
20/04	CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
15/04	CStone Pharmaceuticals Seeks HK$1 Billion via Share Placement
15/04	CStone Pharmaceuticals to place aggregate of 118 million shares at HK$8.97 per placing share
01/04	Adlai Nortye Ltd. Announces President Changes, Effective April 1, 2026
31/03	Gushengtang Holdings Limited Appoints Cao Yanling as A Non-Executive Director with Effect from March 31, 2026